Introduction
Approximately 80% of patients with early stage Hodgkin's lymphoma (HL) given conventional chemotherapy with or without radiotherapy attain a cure, and about 50% of advanced disease patients achieve long-term disease-free survival. 1 The rate of relapse ranges from 10 to 15% in favorable prognosis stages I-II to 30 to 40% in advanced disease. 1, 2 In addition, approximately 10-15% of the patients experience progression of disease after an initial partial response (PR). For patients who fail combined modality treatment, their prognosis is poor. Most do not achieve long-term cure with conventional salvage chemotherapy. 3 Sustained remission after high-dose chemotherapy (HDC) and autologous peripheral skin cell transplant (PSCT) can be achieved in many patients with recurrent or refractory Hodgkin's disease. According to the Autologous Blood and Marrow Transplant Registry data reported by Lazarus et al, the 3-year disease-free survival for HD patients undergoing autotransplant is 30-60%. 4, 5 For patients with advanced stage intermediate and high-grade non-Hodgkin's lymphoma (NHL), long-term disease-free survival is attained with combination chemotherapy in 40-50% of the patients. 6 Durable and long-term disease-free survival is rare with conventional salvage chemotherapy. With the PARMA trial, HDC and autologous stem cell transplant have emerged as a valuable treatment option for those patients with relapsed or primary refractory disease with a 30% long-term survival. 7 The majority of treatment failures following HDC and stem cell transplant for HD and NHD stem from relapses at prior disease sites, emphasizing the important role of radiation in achieving local disease control before stem cell transplant.
In a SWOG trial, intensification by incorporating total body irradiation (TBI) in a preparative regimen with cyclophosphamide, etoposide prior to autologous transplant for NHL decreased the relapse rate, which lead to survival improvement. However, toxic deaths were noted due to infection, hemorrhagic alveolitis or bleeding. 8 The advantages of adjuvant involved field radiation therapy (IFRT) in the treatment of lymphoma prior to transplant include minimizing bulky disease so that HDC is more effective and avoiding exposing reinfused stem cells to myelosuppressive therapy, if it were to be given after HDC. Potential concerns, however, include increased pulmonary morbidity in patients receiving thoracic radiation prior to transplant, and increased incidence of secondary myelodysplasia and thyroid or cardiac toxicity. It is therefore imperative to study the effects of additional pretransplant radiation in the setting of such intensive regimens. The optimal extent, timing and dose of involved field radiation in the transplant setting remain unknown. Furthermore, patients with HL commonly receive IFRT as consolidation and the impact of TBI-containing regimens on morbidity and mortality is unknown. The aim of this study is to retrospectively describe observed toxicity related to the use of involved field radiation therapy followed by total body irradiation (TBI) and HDC in patients undergoing autologous PSCT for relapsed or refractory lymphoma, stratified by the time of radiation exposure (proximal vs distal to TBI), and compare their outcome to the group of patients who did not receive IFRT.
Patient and methods
Between January 1994 and May 2002, 156 patients with relapsed or primary refractory lymphoma including 27 patients with HD were treated with TBI, HDC and autologous PSCT at UCLA. A retrospective chart review was performed to identify patients who had received additional extended or involved field irradiation. The administration of IFRT was based on clinical grounds, according to the judgment of the treating physician. Certain patients received IFRT or somewhat more extended field treatment as part of consolidation of primary chemotherapy, whereas the majority received localized radiation therapy in an effort to control relapsed or refractory disease with inadequate response to salvage chemotherapy, or at sites of previous bulky disease. Response to salvage chemotherapy was defined as complete if the patient achieved remission prior to TBI, and partial if the patient achieved 450% reduction of the sum of the bidimensional products of the nodal masses. Radiation given within 3 months prior to TBI is defined as proximal, whereas radiation given more than 3 months prior to TBI, usually as consolidation of the induction regimen, is defined as remote. For patients deemed to need irradiation for further cytoreduction following salvage chemotherapy, there was coordination with the radiotherapist so that the spot irradiation was usually delivered after sufficient stem cell collection was performed and in continuity with the TBI, in order to avoid interrupted radiation exposure to the tumor mass. This approach is in accordance with principles of radiotherapy whereby continuous irradiation of the tumor mass increases the antitumor effect. All patients received conditioning including TBI (1200 cGy in eight fractions given twice daily) and HDC with etoposide (60 mg/kg) and cyclophosphamide (100 mg/kg), followed by infusion of autologous peripheral stem cells. Patients remained in isolation until the absolute neutrophil count was 4500/ml. Treatment-related mortality is defined as any death occurring within 2 months following PSCT, not related to disease progression.
The Fisher exact test was used to compare and calculate the probability of percentages of patients who died 2 months after undergoing involved field radiation vs those who did not. It was also used to compare and calculate the probability of patients' responses to salvage chemotherapy prior to TBI among those who received IFRT vs those who did not. The Kaplan-Meier analysis was used to depict the probability of survival in 4 years.
Results
Out of 156 patients with relapsed HL and NHL undergoing transplant, 21 patients who had also received IFRT were identified. A total of eight patients had HL and 13 patients had NHL. IFRT was given to 18 patients before TBI (five with HL and 13 with NHL) and in two HL patients after TBI. One additional patient with HL had a remote history of radiation prior to TBI and also received radiation after TBI. A total at 12 patients (three with HL and nine with NHL) received IFRT proximal to transplant, and six (two with HL and four with NHL) received radiation remote to transplant. The median age at the time of PSCT of the group who received IFRT was 45 years (range 20-70), whereas for the whole transplant group it was 51 years (range 19-72). The median number of chemotherapy cycles for both the group who received IFRT and the whole group is 9. Median follow-up was 30 months post transplant.
Morbidity
The most common radiation-related toxicity in those who received IFRT in addition to TBI was noted to be lung toxicity, which occurred in four patients (Table 1) . Three patients had HL and had previously received bleomycin. Pneumonitis occurred in two patients who had radiation proximal to TBI and was an early complication, occurring within 6 months after TBI. One required steroids and is Another radiation-related toxicity observed was hypothyroidism, which occurred in one patient who had radiation remote to PSCT. Both lung and thyroid toxicities occurred in patients who received radiation to the mediastinum, neck and axilla. One case of myelodysplasia was seen in a patient who received mini-mantle field radiation remote to TBI that was subsequently followed by radiation to the abdomen. None developed cardiac toxicity or secondary malignancies ( Table 2 ).
Mortality
Among the 19 patients who received IFRT prior to TBI, five treatment-related deaths occurred within 2 months after TBI (26%, 95% CI: 7-45%). Four out of five had radiation proximal to PSCT and one had received radiation remote to PSCT. No treatment-related death was observed among the two patients who received radiation only following PSCT. Most deaths were related to sepsis and multiorgan failure (Table 3) .
Among the 12 patients who received IFRT proximal to TBI, four treatment-related deaths were noted. In contrast, among the six patients who received IFRT remote to TBI, one treatment-related death was noted. Due to small numbers, the difference does not reach statistical significance (P ¼ 0.38).
The increased incidence of treatment-related deaths in the radiation group seems to be relevant. As mentioned above, five treatment-related deaths were noted in the 19 patients who had IFRT at any time prior to TBI (26%), compared to seven out of 135 patients (5%) who had not received radiation other than TBI prior to autologous PSCT (Po0.05, relative risk: 5). The overall survival at 4 years was 59% in patients who did not receive IFRT and 66% in those who received IFRT (P ¼ 0.48) (Figure 1) . Those who received proximal IFRT had a 66% overall survival as well.
No relationship could be confirmed between treatmentrelated death and location of IFRT. Three deaths occurred among the 13 patients who received thoracic radiation compared to two deaths out of seven patients who received extrathoracic radiation. In addition, there was no relation with the number of prior chemotherapy cycles; the five patients who suffered treatment-related deaths had a median of eight prior chemotherapy cycles.
Prior to TBI and PSCT, 38 patients had complete response (CR) to salvage chemotherapy: four out of 21 (19%) who also had IFRT and 34 out of 135 (25%) who did not. PR was present in 17 (81%) among those who had IFRT and 101 (75%) in those who did not. There seemed to be no difference in pretransplant response status and in treatment-related mortality between in those who received IFRT or those who did not. In fact, among all the 12 patients who suffered treatment-related death, disease status prior to TBI and PSCT was not significantly different in those who received IFRT vs those who did not. In the IFRT group, all five treatment-related deaths occurred among patients with PR; the seven deaths in the non-IFRT group occurred in three patients in CR and four in PR prior to transplant. The difference did not reach statistical significance (P ¼ 0.16).
Discussion
Radiation therapy may be used in lymphoma patients as monotherapy, as an adjunct to conventional chemotherapy, and in the preparative regimen prior to HLC and auto PSCT. In patients with aggressive histologies, radiation therapy typically complements chemotherapy-based Table 2 Radiation-related toxicity in those who received IFRT and TBI Definition of timing when IFRT was given: proximal -less than 3 months prior to TBI; remote -more than 3 months prior to TBI; Post -after TBI. a This patient had received radiation both before and after transplant involving 425% of bone marrow area. Risk of radiation prior to autoSCT C Emmanouilides et al approaches in an effort to cytoreduce an inadequate response to chemotherapy or consolidate a lesion thought to be of high risk for relapse. 9 Consolidation radiation therapy is commonly used following chemotherapy in patients with early-stage or bulky HL, or patients with early-stage aggressive NHL. 10, 11 Upon relapse, radiation therapy is usually employed in an effort to achieve maximal cytoreduction in a patient, hoping to render autologous transplant more successful. Occasionally, radiation to a resistant or dominant tumor mass can be deferred until after completion and recovery from the sequelae of HLC, in order to avoid compounding the toxicities of the IFRT, TBI and HLC. The possible advantage of peri-transplant irradiation has been suggested in nonrandomized studies involving patients with HL. 12, 13 However, the risk benefit ratio of peri-transplant boost IFRT radiation is not clearly defined in HL or NHL.
Radiation-related toxicity
Pulmonary toxicity is a common complication of radiation combined with autologous PSCT leading to increased post-transplant mortality. Yahalom et al 14 and associates reported a 17% fatality rate in 47 patients with HL treated with involved field radiation therapy and total lymphoid irradiation followed by high-dose cyclophosphamide and etoposide and autologous bone marrow transplant. This fatality rate may be correlated with IFRT to the mediastinum given pretransplant. Alveolar hemorrhage is also a well-described complication in patients from the Memorial Sloan-Kettering Cancer Center who had received cyclophosphamide, BCNU, etoposide and TBI. 15 In our study, lung toxicity was confirmed to be a common complication occurring in patients who were treated with radiation to the mediastinum and supraclavicular region, thus strongly suggesting an association of pneumonitis with additional lung irradiation. However, it did not appear to emerge as a significant cause of mortality, possibly due to the relatively small numbers of patients analyzed. Interestingly, remote mediastinal radiation did not seem to predispose to post-TBI pulmonary toxicity in our cohort.
It is disturbing that post-transplant treatment-related mortality was significantly more common in patients who received involved field radiation proximal to the TBIcontaining transplant. Despite the small numbers of patients analyzed, this finding was statistically significant. Although the incidence of pulmonary toxicity seems to be aggregating in patients with HL, the treatment-related mortality seems to be independent of the underlying diagnosis. Also, the specific location of IFRT, however, did not seem to be related to this outcome, which may be counterintuitive. It is possible that the tissue damage induced by radiation and accentuated by the TBI and HLC increase the risk for septic syndromes, which, if uncontrollable, eventually lead to multiorgan failure. It is also known that radiation injury is associated with a systemic cytokine release 16 that may promote vasodilatation or lung damage and may foster a septic syndrome, which may be deleterious in certain cases. More extensive prior chemotherapy treatment did not explain this outcome, although the presence of presumably more resistant tumors may play a role. Our study could not demonstrate an effect of pretransplant disease status, but all toxic deaths occurred in patients in PR, raising the possibility of some association between disease refractoriness and treatmentrelated mortality.
The overall survival at 4 years was the same in the IFRT and the no-IFRT groups (Figure 1 ). The overall survival for the select group of patients who received proximal IFRT was similar. The small number of index patients may preclude a clear determination of the impact on overall outcome, but it seems that a steep decline in survival may be offset by a better control of the tumor.
In clinical practice, the timing of radiation in relation to HLC and autologous PSCT is controversial. The advantages of using radiation before transplant include maximal cytoreduction before HLC. Patients who achieved complete remission before autologous PSCT are reported to have a better outcome than those transplanted in partial remission. 14, 17 Radiation given before transplant is better tolerated hematologically, because it does not interfere with the post translant recovery of the infused stem cells. However, this study suggests that radiation given prior to autologous PSCT, mainly in an effort to convert a PR to a complete one and thus hopefully improve the transplant outcome, may be associated with a high rate of treatmentrelated mortality. Although the numbers of patients analyzed are small, such an adverse effect was not obvious for patients receiving radiation after engraftment. On the other hand, disadvantages of delaying radiation for the post transplant period may include worsening of cytopenias, or even inability to deliver due to incomplete hematologic reconstitution, theoretically increased risk of myelodysplasia and finally less antitumor effect due to the interruption of the radiation to the involved site, since the dose delivered post transplant will have to be reduced commensurate to the TBI exposure.
Our data raise concerns regarding the use of IFRT in the immediate pretransplant period and suggest that the advantage of improving the tumor control with pretransplant irradiation should be carefully weighed against a definite increase in morbidity and mortality. In the absence of randomized trials, a number of important issues remain unresolved concerning the use of adjunctive radiotherapy in Risk of radiation prior to autoSCT the autologous transplant setting. Further investigations are needed to better define the optimal population who may benefit form IFRT prior to HLC, to identify those subsets that are at higher risk of radiation-induced morbidity and to define the optimal extent, dose and timing of radiation.
